{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83d\udcca Detect, Diagnose, Defend: Protecting the Heart During ICI Therapy per IC-OS \ud83e\udec0\ud83e\udded\ud83d\udee1\ufe0f","description":"\ud83d\ude80 Immune checkpoint inhibitors have transformed cancer care\u2014but they come with a cardiovascular shadow. A new International Cardio-Oncology Society (IC-OS) position statement offers the clearest guidance yet on myocarditis, pericarditis, arrhythmias, ACS, and noninflammatory HF linked to ICI therapy. \ud83e\udec0\ud83d\udca1 &amp;nbsp; Key insights include: \u2022 Early recognition with troponin, ECG, and CMR \ud83e\uddea\ud83d\udcca \u2022 Smoldering vs. nonsevere vs. fulminant myocarditis distinctions \ud83d\udd0d \u2022 Steroid-first management and the evolving role of abatacept + JAK inhibitors \ud83d\udc8a \u2022 Nuanced approaches to ICI rechallenge when cancer control demands it \ud83d\udd04\ud83c\udfaf \u2022 The essential role of multidisciplinary cardio-oncology teams \ud83e\udd1d &amp;nbsp; This is a must-read for anyone navigating the intersection of oncology, cardiology, and immunotherapy. \ud83c\udf10\ud83d\udd25 ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39311690\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/196292270"}